Clinical trials
Phase 1 Hemophilia A trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
81 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 2 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 5 |
| 2011 | 5 |
| 2012 | 8 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 60 |
| Recruiting | 6 |
| Terminated | 5 |
| Unknown status | 4 |
| Withdrawn | 3 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 24 |
| Bayer | 10 |
| Pfizer | 5 |
| Baxalta now part of Shire | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 3 |
| Bioverativ Therapeutics Inc. | 2 |
| Catalyst Biosciences | 2 |
| Emory University | 2 |
| Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2 |
| OPKO Health, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemophilia A | 81 |
| Hemophilia B | 22 |
| Blood Coagulation Disorders | 2 |
| Coagulation Protein Disorders | 1 |
| Factor VII Deficiency | 1 |
| HIV Infections | 1 |
| Hemorrhage | 1 |
| Hepatitis C | 1 |
| Hepatitis C, Chronic | 1 |
| Liver Cirrhosis | 1 |
Trials
Showing 26 to 50 of 81. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.